Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
ASLAN Pharmaceuticals Ltd (ASLN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 6-K Quarterly results
Docs: "6-K",
"ASLAN PHARMACEUTICALS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Positive topline data reported in July from TREK-AD, a Phase 2b study of eblasakimab that met the primary endpoint across three dose arms with statistical significance. The data established eblasakimab, a potential first-in-class antibody, as the first biologic in moderate-to-severe atopic dermatitis to demonstrate a competitive efficacy profile with once-monthly dosing from initiation - Data supports advancement of eblasakimab into Phase 3 clinical development program in 2024 - Readouts from TREK-DX Phase 2 study of eblasakimab and FAST-AA Phase 2a study of farudodstat both expected in the first quarter of 2024 - Company maintains healthy operating position with $40.9 million in cash and ca..."
08/12/2022 6-K Quarterly results
Docs: "FORM 6-K",
"ASLAN PHARMACEUTICALS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE",
"ASLAN Pharmaceuticals Limited Financial Statements for the six months ended June 30, 2022"
04/22/2021 6-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy